Mark D Andrews Selected Research

PF 3246799

5/2011

Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark D Andrews Research Topics

Disease

1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Pain (Aches) 11/2014
1	Urinary Incontinence 05/2011
1	Tinea (Ringworm) 05/2008
1	Tinea Capitis 05/2008
1	Tinea Pedis (Athlete's Foot) 05/2008
1	Onychomycosis (Tinea Unguium) 05/2008
1	Infections 05/2008

Drug/Important Bio-Agent (IBA)

1	InterleukinsIBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	CytokinesIBA 01/2022
1	Oxycodone (Oxycontin)FDA LinkGeneric 11/2014
1	CationsIBA 11/2014
1	5-HT2C Serotonin ReceptorIBA 05/2011
1	AzepinesIBA 05/2011
1	PF 3246799IBA 05/2011
1	Terbinafine (Lamisil)FDA LinkGeneric 05/2008
1	Fluconazole (Zonal)FDA LinkGeneric 05/2008
1	Antifungal AgentsIBA 05/2008
1	Itraconazole (Sporanox)FDA LinkGeneric 05/2008
1	Griseofulvin (Grifulvin V)FDA LinkGeneric 05/2008

Therapy/Procedure

1	Therapeutics 05/2008